Trends in Psychiatry and Psychotherapy
https://trends.org.br/article/doi/10.1590/2237-6089-2016-0076
Trends in Psychiatry and Psychotherapy
Review Article

Hepatitis C: clinical and biological features related to different forms of cocaine use

Hepatite C: características clínicas e biológicas relacionadas às diferentes formas de uso da cocaína

Silvia Bassani Schuch-Goi; Juliana Nichterwitz Scherer; Felix Henrique Paim Kessler; Anne Orgler Sordi; Flavio Pechansky; Lisia von Diemen

http://dx.doi.org/10.1590/2237-6089-2016-0076 Trends Psychiatry Psychother, vol.39, n4, p.285-292, 2017
PDF
SciELO
Downloads: 0
Views: 330

Abstract

Abstract Introduction Hepatitis C virus (HCV) infection is related with several liver diseases such as cirrhosis and hepatocellular carcinomas, leading to more than 0.5 million deaths every year and to a great global burden. It is known that injection drug users show a high prevalence of HCV infection, being considered a risk group for this disease. Cocaine users seem to be in greater risk than other drug users, and several hypotheses for this association are being studied. Aim To review data on HCV infection in cocaine users, taking into consideration the relevance of the different routes of drug administration and other risk behaviors. Methods This was a narrative review performed in the main scientific databases. Results and conclusion Data suggest that cocaine use could be associated with HCV infection due to the specificities of cocaine consumption pattern, even in those subjects who do not inject drugs, in addition to other risky behaviors, such as tattooing and unprotected sex. Injectable cocaine users seem to be more susceptible to contamination than users who do not inject drugs. However, evidence is pointing to the possibility of infection by sharing drug paraphernalia other than syringes. Moreover, specific immune system impairments caused by cocaine use are also being linked with HCV infection susceptibility, persistence and increased pathological effects.

Keywords

HCV infection, cocaine, immune system, drug users, injection drugs, non-injection drugs

Resumo

Resumo Introdução O vírus da hepatite C (HCV) está relacionado com graves patologias hepáticas, como a cirrose e o carcinoma hepatocelular, causando mais de meio milhão de mortes todos os anos, o que reflete um problema de saúde mundial. Sabe-se que usuários de drogas injetáveis possuem alta prevalência de infecção pelo HCV, sendo por isso considerados um dos maiores grupos de risco. Usuários de cocaína parecem ter maior risco de contrair o vírus do que usuários de outras drogas, e diversas hipóteses para essa associação estão sendo estudadas. Objetivo Revisar evidências de associação da infecção pelo HCV em usuários de cocaína, considerando a relevância das diferentes formas de administração da droga e comportamentos de risco. Métodos Esta foi uma revisão narrativa realizada nos principais bancos de dados científicos. Resultados e conclusão As evidências atuais sugerem que o uso de cocaína pode estar associado com a infecção por HCV devido às especificidades do padrão de consumo da droga, mesmo naqueles indivíduos que não fazem uso de drogas injetáveis, além de outros comportamentos de risco, como tatuagens e sexo desprotegido. Usuários de cocaína injetável parecem estar mais suscetíveis à contaminação do que usuários de cocaína não injetável. Entretanto, há a possibilidade de infecção devido ao compartilhamento de outros equipamentos de uso além das seringas (cachimbos, por exemplo). Além disso, prejuízos do sistema imune causados pela cocaína também parecem estar associados com a suscetibilidade de infecção pelo HCV, além da manutenção e piora dos sintomas da doença.

Palavras-chave

HCV, cocaína, sistema imune, uso de drogas, drogas injetáveis, drogas não-injetáveis

References

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-38.

Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.

De P, Roy E, Boivin JF, Cox J, Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepat. 2008;15:279-92.

Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733-45.

Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379:55-70.

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-83.

Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL. Non-injection drug use and Hepatitis C Virus: a systematic review. Drug Alcohol Depend. 2007;89:1-12.

Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse. 2004;39:211-24.

McMahon JM, Simm M, Milano D, Clatts M. Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob. 2004;3:6.

Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol. 2006;47:330-42.

Kaushik KS, Kapila K, Praharaj AK. Shooting up: the interface of microbial infections and drug abuse. J Med Microbiol. 2011;60:408-22.

Pellegrino TC, Dunn KL, Bayer BM. Mechanisms of cocaine-induced decreases in immune cell function. Int Immunopharmacol. 2001;1:665-75.

Kubera M, Filip M, Basta-Kaim A, Nowak E, Siwanowicz J, Zajicova A. The effect of cocaine sensitization on mouse immunoreactivity. Eur J Pharmacol. 2004;483:309-15.

Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev. 2003;16:209-19.

Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence?. Lancet Infect Dis. 2005;5:296-304.

Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis. 2004;190:1919-26.

Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol. 2003;163:1167-75.

Wang CQ, Li Y, Douglas SD, Wang X, Metzger DS, Zhang T. Morphine withdrawal enhances hepatitis C virus replicon expression. Am J Pathol. 2005;167:1333-40.

Zhou Y, Sun L, Wang X, Zhou L, Li J, Liu M. Heroin use promotes HCV infection and dysregulates HCV-related circulating microRNAs. J Neuroimmune Pharmacol. 2015;10:102-10.

Napuri J, Pilakka-Kanthikeel S, Raymond A, Agudelo M, Yndart-Arias A, Saxena SK. Cocaine enhances HIV-1 infectivity in monocyte derived dendritic cells by suppressing microRNA-155. PLoS One. 2013;8.

Mantri CK, Pandhare Dash J, Mantri JV, Dash CC. Cocaine enhances HIV-1 replication in CD4+ T cells by down-regulating MiR-125b. PLoS One. 2012;7.

Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, Miyanishi K. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut. 2006;55:1801-8.

Reynolds JL, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Schwartz SA. Proteomic analyses of the effects of drugs of abuse on monocyte-derived mature dendritic cells. Immunol Invest. 2009;38:526-50.

Ye L, Peng JS, Wang X, Wang YJ, Luo GX, Ho WZ. Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. J Viral Hepat. 2008;15:261-70.

Kubera M, Filip M, Budziszewska B, Basta-Kaim A, Wydra K, Leskiewicz M. Immunosuppression induced by a conditioned stimulus associated with cocaine self-administration. J Pharmacol Sci. 2008;107:361-9.

Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18:352-8.

Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436-41.

Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, Cooper HL, Scheinmann R, Stern R. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Soc Sci Med. 2009;68:579-90.

Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18:341-51.

Miller CL, Johnston C, Spittal PM, Li K, Laliberté N, Montaner JS. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002;36:737-42.

Oliveira Filho AB, Sawada L, Pinto LC, Locks D, Bahia SL, Castro JA. Epidemiological aspects of HCV infection in non-injecting drug users in the Brazilian state of Para, eastern Amazon. Virol J. 2014;11:38.

Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2012;107:1057-65.

Mathei C, Shkedy Z, Denis B, Kabali C, Aerts M, Molenberghs G. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J Viral Hepat. 2006;13:560-70.

Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes--role in pathogenesis of disease and response to therapy. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:229-40.

Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virol J. 2010;7:96.

Roux P, Fugon L, Jones JD, Comer SD. Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection. Am J Addict. 2013;22:613-8.

Erfan S, Hashim AH, Shaheen M, Sabry N. Effect of comorbid depression on substance use disorders. Subst Abus. 2010;31:162-9.

Gu J, Lau JT, Chen H, Chen X, Liu C, Liu J. Mental health and interpersonal factors associated with HIV-related risk behaviors among non-institutionalized female injection drug users who are also sex workers in China. Women Health. 2010;50:20-36.

Gu J, Lau JT, Chen H, Tsui H, Ling W. Prevalence and factors related to syringe sharing behaviours among female injecting drug users who are also sex workers in China. Int J Drug Policy. 2011;22:26-33.

Jones DL, Waldrop-Valverde D, Gonzalez P, Mack A, Kumar AM, Ownby R. Mental health in HIV seronegative and seropositive IDUs in South Florida. AIDS Care. 2010;22:152-8.

Severtson SG, Mitchell MM, Hubert A, Latimer W. The relationship between performance on the Shipley Institute of Living Scale (SILS) and hepatitis C infection among active injection drug users in Baltimore, Maryland. Am J Drug Alcohol Abuse. 2010;36:61-5.

Hopwood CJ, Morey LC, Skodol AE, Sanislow CA, Grilo CM, Ansell EB. Pathological personality traits among patients with absent, current, and remitted substance use disorders. Addict Behav. 2011;36:1087-90.

Iskandar S, Kamal R, De Jong CA. Psychiatric comorbidity in injecting drug users in Asia and Africa. Curr Opin Psychiatry. 2012;25:213-8.

Morissette C, Cox J, De P, Tremblay C, Roy E, Allard R. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Int J Drug Policy. 2007;18:204-12.

Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis. 2009;9:113.

Shannon K, Rusch M, Morgan R, Oleson M, Kerr T, Tyndall MW. HIV and HCV prevalence and gender-specific risk profiles of crack cocaine smokers and dual users of injection drugs. Subst Use Misuse. 2008;43:521-34.

Sa LC, Araujo TM, Griep RH, Campelo V, Monteiro CF. Seroprevalence of hepatitis C and factors associated with this in crack users. Rev Lat Am Enfermagem. 2013;21:1195-202.

Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis. 2012;206:654-61.

Fischer B, Powis J, Firestone Cruz M, Rudzinski K, Rehm J. Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. Eur J Gastroenterol Hepatol. 2008;20:29-32.

Aaron S, McMahon JM, Milano D, Torres L, Clatts M, Tortu S. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis. 2008;47:931-4.

Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmid DS. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:87-92.

Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend. 2005;79:389-95.

Macias J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008;28:781-6.

Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-6.

Vivas-Arceo C, Benavides SA, De Jesus Trujillo J, Panduro A, Rivas-Estilla AM. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Res. 2003;25:115-23.

Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881-9.

Cavlek TV, Margan IG, Lepej SZ, Kolaric B, Vince A. Seroprevalence, risk factors, and hepatitis C virus genotypes in groups with high-risk sexual behavior in Croatia. J Med Virol. 2009;81:1348-53.

Inciardi JA, Surratt HL, Kurtz SP. HIV, HBV, and HCV infections among drug-involved, inner-city, street sex workers in Miami, Florida. AIDS Behav. 2006;10:139-47.

Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology. 2010;52:1497-505.

Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend. 2000;58:219-26.

Tull MT, Gratz KL, Weiss NH. Exploring associations between borderline personality disorder, crack/cocaine dependence, gender, and risky sexual behavior among substance-dependent inpatients. Personal Disord. 2011;2:209-19.

Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36:S99-S105.

Duff P, Tyndall M, Buxton J, Zhang R, Kerr T, Shannon K. Sex-for-Crack exchanges: associations with risky sexual and drug use niches in an urban Canadian city. Harm Reduct J. 2013;10:29.

Diemen L von, De Boni R, Kessler F, Benzano D, Pechansky F. Risk behaviors for HCV- and HIV-seroprevalence among female crack users in Porto Alegre, Brazil. Arch Womens Ment Health. 2010;13:185-91.

Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis. 2012;54:1167-78.

Campollo O, Roman S, Panduro A, Hernandez G, Diaz-Barriga L, Balanzario MC. Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug Alcohol Depend. 2012;123:269-72.

Xue J, Zhu H, Chen Z. Therapeutic vaccines against hepatitis C virus. Infect Genet Evol. 2014;22:120-9.

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9.

Grebely J, Lima VD, Marshall BD, Milloy MJ, DeBeck K, Montaner J. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. PLoS One. 2014;9.

Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57(^sSuppl 2):S32-8.

Mateu-Gelabert P, Treloar C, Calatayud VA, Sandoval M, Zurian JC, Maher L. How can hepatitis C be prevented in the long term?. Int J Drug Policy. 2007;18:338-40.

Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol. 2015;7:616-27.

Grebely J, Dore GJ. What is killing people with hepatitis C virus infection?. Semin Liver Dis. 2011;31:331-9.

Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57:1379-90.

Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol. 2013;58:31-7.

Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631-40.

Bertoni N, Burnett C, Cruz MS, Andrade T, Bastos FI, Leal E. Exploring sex differences in drug use, health and service use characteristics among young urban crack users in Brazil. Int J Equity Health. 2014;13:70.

Cox J, De P, Morissette C, Tremblay C, Stephenson R, Allard R. Low perceived benefits and self-efficacy are associated with hepatitis C virus (HCV) infection-related risk among injection drug users. Soc Sci Med. 2008;66:211-20.

Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141-7.

Severtson SG, Hedden SL, Martins SS, Latimer WW. Patterns of Cognitive Impairments Among Heroin and Cocaine Users: The Association With Self-Reported Learning Disabilities and Infectious Disease. J Learn Disabil. 2010.

6169deb3a953955a7e1bd3f4 trends Articles
Links & Downloads
2238-0019 (Electronic)
Trends Psychiatry Psychother ©2024 All rights reserved.

Trends Psychiatry Psychother

Share this page
Page Sections